The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Try the newly designed Company Pages!
Switch now

Biomarin Pharmaceuticals

  • BMRN
  • NASDAQ
  • Consumer Products
  • Latest 62.08
  • Currency US$
  • Change 1.70
  • Percent Change 2.816 %
  • Volume 1,376,160
  • Wed Jul 23, 2014 04:00 PM EDT NASDAQ data delayed 15 minutes.
  • Open 61.48
  • Previous Close 60.38
  • High 63.05
  • Low 60.164
  • Bidx0 0.0000
  • Askx0 0.0000
  • 52-week High02/27 84.25
  • 52-week Low04/15 55.04
  • Beta 0.691
  • Market Cap 8,999.12M
  • EPS -1.25
  • P/E
  • Forward P/E
  • PEG
  • Annual Dividend 0.0000
  • Yield

News

Financials & Calendars

Income Statement

  • Sales $572,100,000
  • Earnings $-174,660,000
  • Return on Equity n/a

Cash Flow

  • Cash Flow --
  • Cash $639,770,000
  • Current Ratio 7.99

12 months ended Mar 31, 2014.

Trailing 12 month results shown above.
All data is in U.S. dollars.

Balance Sheet

  • Assets $2,340,720,000
  • Liabilities $880,600,000
  • Liabilities-to-Equity Ratio 0.60

Price Ratios

  • Price to Sales 15.73
  • Price to Book 6.16
  • Price to Cash Flow n/a

Event Calendar

Event Last   Next  
Earnings May 1 $-0.50 Jul 30 $-0.41
Surprises May 1 -46.00% n/a n/a
Dividends n/a n/a n/a n/a
Splits n/a -- n/a n/a

12 months ended Jul 23, 2014.

A look at major corporate events and financial announcements that are coming up.

Company Information

About the Company

BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.

Related Securities
Symbol Type Latest % Chg

Officers

  • Pierre LaPalme Chairman and Director
  • Jean-Jacques Bienaime Chief Executive Officer
  • Company Type: n/a
  • Company Status: n/a
  • Full-time Employees: n/a
  • Incorporation: United States,
    n/a
  • Top 1000 Ranking: Profit: n/a
    Revenue: n/a
    Assets: n/a

Head Office

770 Lindaro Street
San Rafael, CA
94949

Phone: (415)-506-6700
Fax: (415)-3827889

ir@bmrn.com
www.bmrn.com

Ideas & Discussion

Live Discussion of BMRN on StockTwits